🇺🇸 KISUNLA in United States

FDA authorised KISUNLA on 2 July 2024

Marketing authorisation

FDA — authorised 2 July 2024

Application: BLA761248
Marketing authorisation holder: ELI LILLY CO
Local brand name: KISUNLA
Indication: INJECTABLE — INJECTION
Status: approved

The FDA approved KISUNLA, a new molecular entity and new combination, for marketing by ELI LILLY CO on 2024-07-02. The approval was granted under the standard expedited pathway. The indications for KISUNLA are classified as Type 1 New Molecular Entity and Type 4 New Combination.

Read official source →

KISUNLA in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is KISUNLA approved in United States?

Yes. FDA authorised it on 2 July 2024.

Who is the marketing authorisation holder for KISUNLA in United States?

ELI LILLY CO holds the US marketing authorisation.